Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study. Analysis of patients (pts) with unresectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results